Increased Levels of GFAP in the Cerebrospinal Fluid in Three Subtypes of Genetically Confirmed Alexander Disease

 

 Buy Article Permissions and Reprints

Abstract

GFAP levels in the CSF were highly elevated in three genetically confirmed cases of Alexander disease clinically conforming with infantile, early and late juvenile forms. No other CSF abnormalities were detected. Assay of CSF-GFAP may prove to be a rapid and cost-effective screening test in clinical variants of Alexander disease and an indicator of GFAP gene mutations.

References

• 1 Blennow K, Wallin A, Ågren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical diagnostic marker for axonal degeneration in Alzheimer's disease?.  Mol Chem Neuropathol. 1995;  26 231-245
  CrossrefPubMedGoogle Scholar
• 2 Blennow M, Hagberg H, Rosengren L. Glial fibrillary acidic protein in the cerebrospinal fluid: a possible indicator of prognosis in full-term asphyxiated newborn infants?.  Pediatr Res. 1995;  37 260-264
  PubMedGoogle Scholar
• 3 Brockmann K, Dechent P, Meins M, Haupt M, Sperner J, Stephani U, Frahm J, Hanefeld F. Cerebral proton magnetic resonance spectroscopy in infantile Alexander disease.  J Neurol. 2003;  250 300-306
  PubMedGoogle Scholar
• 4 Ehlers S, Kyllerman M, Rosengren L. Analysis of glial fibrillary acidic protein in the cerebrospinal fluid of children investigated for encephalopathy.  Neuropediatrics. 1994;  24 129-133
  PubMedGoogle Scholar
• 5 Johnson A B, Brenner M. Alexander's disease: clinical, pathologic, and genetic features.  J Child Neurol. 2003;  18 625-632
  CrossrefPubMedGoogle Scholar
• 6 Johnson A B. Alexander disease: A review and the gene.  Int J Dev Neurosci. 2002;  20 391-394
  PubMedGoogle Scholar
• 7 Kristiansdottir R, Uvebrant P, Rosengren L. Glial fibrillary acidic protein and neurofilament in children with cerebral white matter abnormalities.  Neuropediatrics. 2001;  32 307-312
  Article in Thieme ConnectPubMedGoogle Scholar
• 8 Mignot C, Boespflug-Tanguy O, Gelot A, Dautigny A, Pham-Dinh D, Rodriguez D. Alexander disease: putative mechanisms of an astrocytic encephalopathy.  Cell Mol Life Sci. 2004;  61 369-385
  CrossrefPubMedGoogle Scholar
• 9 Rosengren L E, Wikkelsø C, Hagberg L. A sensitive ELISA for glial fibrillary acidic protein: application in CSF of adults.  J Neurosci Meth. 1994;  51 197-204
  PubMedGoogle Scholar
• 10 Rosengren L E, Karlsson J ‐E, Karlsson J-O, Persson L I, Wikkelsø C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament proteins in CSF.  J Neurochem. 1996;  67 2013-2018
  PubMedGoogle Scholar
• 11 Li R, Johnson A B, Salomons G, Goldman J E, Naidu S, Quinlan R, Cree B, Ruyle S Z, Banwell B, D'Hooghe M, Siebert J R, Rolf C M, Cox H, Reddy A, Gutierrez-Solana L G, Collins A, Weller R O, Messing A, van der Knaap M S, Brenner M. Glial fibrillary acidic protein mutations in infantile, juvenile, and adult forms of Alexander disease.  Ann Neurol. 2005;  57 310-326
  CrossrefPubMedGoogle Scholar
• 12 Lortie A, Lesage J, Montplaisir J, Brais B, Cossette P. Adult Alexander disease with autosomal dominant transmission: a distinct entity caused by a mutation in the glial fibrillar acid protein gene.  Arch Neurol. 2003;  60 1307-1312
  CrossrefPubMedGoogle Scholar
• 13 Studahl M, Rosengren L, Günther G, Hagberg L. Difference in pathogenesis between herpes simplex virus type 1 encephalitis and tick-borne encephalitis demonstrated by means of cerebrospinal fluid markers of glial and neuronal destruction.  J Neurol. 2000;  247 636-642
  PubMedGoogle Scholar
• 14 Stumpf E, Masson H, Duquetta A, Berthelet F, McNabb J, Lortie A, Lesague J, Montpalisir J, Brais B, Cossette P. Adult Alexander disease with autosomal dominant transmission.  Arch Neurol. 2003;  60 1307-1312
  CrossrefPubMedGoogle Scholar

MD, PhD M. Kyllerman

Neuropediatrics
Queen Silvia Children's Hospital
Sahlgrenska University

41685 Göteborg

Sweden

Email: marten.kyllerman@vgregion.se